- Authors:
- Luanne M Metz,
- David K B Li,
- Anthony L Traboulsee,
- Pierre Duquette,
- Misha Eliasziw,
- Graziela Cerchiaro,
- Jamie Greenfield,
- Andrew Riddehough,
- Michael Yeung,
- Marcelo Kremenchutzky,
- Galina Vorobeychik,
- Mark S Freedman,
- Virender Bhan,
- Gregg Blevins,
- James J Marriott,
- Francois Grand'Maison,
- Liesly Lee,
- Manon Thibault,
- Michael D Hill,
- V Wee Yong,
-
N Engl J Med 2017 06;376(22):2122-2133
From the Cumming School of Medicine and the Hotchkiss Brain Institute, Calgary, AB (L.M.M., G.C., J.G., M.Y., M.D.H., V.W.Y.), the University of British Columbia, Vancouver (D.K.B.L., A.L.T., A.R.), the University of Montreal, Montreal (P.D.), Western University, London, ON (M.K.), Fraser Health MS Clinic, Burnaby, BC (G.V.), the University of Ottawa and the Ottawa Hospital Research Institute, Ottawa (M.S.F.), Dalhousie University, Halifax, NS (V.B.), the University of Alberta, Edmonton (G.B.), the University of Manitoba, Winnipeg (J.J.M.), Clinique Neuro Rive-Sud, Greenfield Park, QC (F.G.), the University of Toronto, Toronto (L.L.), and CHA-Hôpital Enfant-Jésus, Quebec, QC (M.T.) - all in Canada; and Tufts University, Boston (M.E.).
Background: On the basis of encouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocycline reduces the risk of conversion from a first demyelinating event (also known as a clinically isolated syndrome) to multiple sclerosis.
Methods: During the period from January 2009 through July 2013, we randomly assigned participants who had had their first demyelinating symptoms within the previous 180 days to receive either 100 mg of minocycline, administered orally twice daily, or placebo. Administration of minocycline or placebo was continued until a diagnosis of multiple sclerosis was established or until 24 months after randomization, whichever came first.
Read More 